CGTX logo

CGTX Cognition Therapeutics, Inc.

NASDAQ Global Market · Biotechnology · Healthcare

$0.58
-0.02 (-3.06%)

Cognition Therapeutics, Inc. is a biopharmaceutical company in the clinical stage, focused on identifying and advancing small molecule treatments. The firm's research and development efforts are primarily directed towards age-related neurodegenerative conditions affecting the central nervous system, as well as retinal disorders. Its most advanced experimental therapy is CT1812, which acts as a sig…

Market Cap: $55.37Mwww.cogrx.com

Price

No data yet.

Social Signal Score

44
5d
—
30d
46
6 mentions
—
60d
42
8 mentions
—
90d
42
8 mentions
—
news: 8

Analyst Ratings

7 analysts
Buyconsensus
Strong Buy 0Buy 6Hold 1Sell 0Strong Sell 0
Avg price target$3+415.3%
Low $3Median $3High $3
Current Consensus

Revenue

$0.00
$0.00
Mar 2020Sep 2026

Analyst Estimates

FY2025
$-0.39
$-0.40–$-0.38
3 analysts
FY2026
$-0.19
$-0.23–$-0.16
3 analysts
FY2027
$-0.18
$-0.21–$-0.15
2 analysts

Consensus estimates, not results. Via Financial Modeling Prep.

Company Profile

CEO
Lisa Ricciardi
Sector
Healthcare
Industry
Biotechnology
Employees
14
Beta
1.80
Country
US
Piotroski score
2 / 9 (Weak)
Altman Z-score
-3.00
www.cogrx.com